Clinical Trial Update: Human Challenge Study to Evaluate the Efficacy of MV-012-968 Vaccine [Phase 2]

View source ↗

Summary

Phase 2 human challenge study evaluating MV-012-968 vaccine for respiratory syncytial virus (RSV) infection has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infection

Drugs mentioned

• MV-012-968 (MV-012-968)

Snippet

Sponsor: Meissa Vaccines, Inc. | Conditions: RSV Infection | Phase 2 | Status: COMPLETED